Post-trial Access in Maternal Vaccine Trials

Abstract

Provisions for post-trial access (PTA) of the experimental intervention are required before the start of a clinical trial. Although there has been ample attention for PTA in the context of preventive vaccine research, discussions on PTA barely include maternal vaccine trials in which mother–infant pairs are exposed to the intervention. In maternal vaccination trials, specific PTA arrangements are required because pregnancy is transient and PTA may apply to the next pregnancy or the child. In this article, we examine the application and adherence to PTA in the context of maternal vaccine trials. We focused on differences between publications before and after 2000 when international ethical guidance documents formalized PTA requirements. Randomized maternal vaccine trials were included after a systematic search for clinical trials in phases II and III with a maternal vaccine as intervention. We used PTA as defined at the time of publication in the World Medical Association's Declaration of Helsinki (DoH) or in the ethical guidelines of the Council for International Organizations of Medical Sciences (CIOMS). In addition, we investigated whether PTA was included in the trial design. Therefore, we contacted principal investigators (PI’s) of the publications found in the review to fill out a questionnaire regarding provisions for PTA. Before and after 2000, no trial articles examined in the systematic review described PTA in their trial publication (0/7, 0% and 0/17, 0%, respectively). In addition, more than half of the PI’s of the trials found were not familiar with PTA recommendations in international ethical guidelines. Most cases of PTA included making knowledge available by publishing the results of the trial. The revision of the DoH in 2002 and the CIOMS ethical guidelines in 2002 has not resulted in increased PTA provisions for maternal vaccination trials. PTA is a shared responsibility of various stakeholders including sponsors, Institutional Review Boards, regulators, political entities, and researchers. Inclusion of PTA provisions in trial protocols and publications on maternal vaccination trials is essential to increase transparency on the form and content of these provisions.

Keywords

post-trial access - maternal vaccination - vaccine trials - research - ethical

• References

• 1 Marchant A, Sadarangani M, Garand M. , et al. Maternal immunisation: collaborating with mother nature. Lancet Infect Dis 2017; 17 (07) e197-e208
• 2 Chu HY, Englund JA. Maternal immunization. Clin Infect Dis 2014; 59 (04) 560-568
• 3 Vojtek I, Dieussaert I, Doherty TM. , et al. Maternal immunization: where are we now and how to move forward?. Ann Med 2018; 50 (03) 193-208
• 4 MacDougall DM, Halperin SA. Improving rates of maternal immunization: Challenges and opportunities. Hum Vaccin Immunother 2016; 12 (04) 857-865
• 5 PATH. RSV Vaccine and mAb Snapshot - PATH Vaccine Resource Library. Cited May 12, 2018. Available at: http://www.path.org/vaccineresources/details.php?i=1562 . Accessed March 29, 2019
• 6 Council for International Organization of Medical Sciences (CIOMS) in collaboration with the World Health Organization (WHO). Final CIOMS Guidelines 2016. Cited December 16, 2016. Available at: https://cioms.ch/wp-content/uploads/2017/01/WEB-CIOMS-EthicalGuidelines.pdf
• 7 Ethical and Policy Issues in International Research: Clinical Trials in Developing Countries VOLUMEI Report and Recommendations of the National Bioethics Advisory Commission. 2001 . Available at: https://bioethicsarchive.georgetown.edu/nbac/clinical/Vol1.pdf
• 8 The ethics of research related to healthcare in developing countries NUFFIELD COUNCIL ON BIOETHICS. Available at: http://nuffieldbioethics.org/wp-content/uploads/2014/07/Ethics-of-research-related-to-healthcare-in-developing-countries-I.pdf
• 9 WMA Declaration of Helsinki - Ethical principles for medical research involving human subjects. Available at: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/ . Accessed May 30, 2019
• 10 Haire B, Jordens C. Mind the gap: an empirical study of post-trial access in HIV biomedical prevention trials. Developing World Bioeth 2015; 15 (02) 85-97
• 11 Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev 2016; 5 (01) 210
• 12 Website World Health Organization. Health topics, vaccines. Available at: http://www.who.int/topics/vaccines/en/ . Accessed January 10, 2018
• 13 Moher D, Liberati A, Tetzlaff J, Altman DG. ; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6 (07) e1000097
• 14 Quiambao BP, Nohynek HM, Käyhty H. , et al. Immunogenicity and reactogenicity of 23-valent pneumococcal polysaccharide vaccine among pregnant Filipino women and placental transfer of antibodies. Vaccine 2007; 25 (22) 4470-4477
• 15 Munoz FM, Englund JA, Cheesman CC. , et al. Maternal immunization with pneumococcal polysaccharide vaccine in the third trimester of gestation. Vaccine 2001; 20 (5-6): 826-837
• 16 Shahid NS, Steinhoff MC, Roy E, Begum T, Thompson CM, Siber GR. Placental and breast transfer of antibodies after maternal immunization with polysaccharide meningococcal vaccine: a randomized, controlled evaluation. Vaccine 2002; 20 (17-18): 2404-2409
• 17 Mulholland K, Suara RO, Siber G. , et al. Maternal immunization with Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in The Gambia. JAMA 1996; 275 (15) 1182-1188
• 18 Newell KW, Dueñas Lehmann A, LeBlanc DR, Garces Osorio N. The use of toxoid for the prevention of tetanus neonatorum. Final report of a double-blind controlled field trial. Bull World Health Organ 1966; 35 (06) 863-871
• 19 Koren G, Money D, Boucher M. , et al. Serum concentrations, efficacy, and safety of a new, intravenously administered varicella zoster immune globulin in pregnant women. J Clin Pharmacol 2002; 42 (03) 267-274
• 20 Munoz FM, Piedra PA, Glezen WP. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 2003; 21 (24) 3465-3467
• 21 Jackson LA, Patel SM, Swamy GK. , et al. Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women. J Infect Dis 2011; 204 (06) 854-863
• 22 Tielsch JM, Steinhoff M, Katz J. , et al. Designs of two randomized, community-based trials to assess the impact of influenza immunization during pregnancy on respiratory illness among pregnant women and their infants and reproductive outcomes in rural Nepal. BMC Pregnancy Childbirth 2015; 15 (01) 40
• 23 Omer SB, Richards JL, Madhi SA. , et al; BMGF Supported Maternal Influenza Immunization Trials Investigators Group. Three randomized trials of maternal influenza immunization in Mali, Nepal, and South Africa: methods and expectations. Vaccine 2015; 33 (32) 3801-3812
• 24 Tsatsaris V, Capitant C, Schmitz T. , et al. Maternal immune response and neonatal seroprotection from a single dose of a monovalent nonadjuvanted 2009 Influenza A(H1N1) vaccine: A Single-Group Trial. Ann Intern Med 2011; 155: 733-741
• 25 Abzug MJ, Nachman SA, Muresan P. , et al. Safety and immunogenicity of 2009 pH1N1 vaccination in HIV-infected pregnant women. Clin Infect Dis 2013; 56 (10) 1488-1497
• 26 Madhi SA, Cutland CL, Kuwanda L. , et al; Maternal Flu Trial (Matflu) Team. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med 2014; 371: 918-931
• 27 Zaman K, Roy E, Arifeen SE. , et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008; 359 (15) 1555-1564
• 28 Salama MM, Hady OA, Ashour W. , et al. A randomized controlled trial [corrected] administration of tetanus toxoid (TT) versus tetanus and reduced diphtheria (Td) in pregnant women. J Clin Immunol 2009; 29 (04) 524-531
• 29 Donders GG, Halperin SA, Devlieger R. , et al. Maternal immunization with an investigational trivalent group B streptococcal vaccine: a randomized controlled trial. Obstet Gynecol 2016; 127 (02) 213-221
• 30 Madhi SA, Cutland CL, Jose L. , et al. Safety and immunogenicity of an investigational maternal trivalent group B Streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial. Lancet Infect Dis 2016; 16 (08) 923-934
• 31 Heyderman RS, Madhi SA, French N. , et al. Group B Streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial. Lancet Infect Dis 2016; 16 (05) 546-555
• 32 Binks MJ, Moberley SA, Balloch A. , et al. PneuMum: Impact from a randomised controlled trial of maternal 23-valent pneumococcal polysaccharide vaccination on middle ear disease amongst indigenous infants, Northern Territory, Australia. Vaccine 2015; 33 (48) 6579-6587
• 33 Daly KA, Scott Giebink G, Lindgren BR. , et al. Maternal immunization with pneumococcal 9-valent conjugate vaccine and early infant otitis media. Vaccine 2014; 32 (51) 6948-6955
• 34 Lopes CR, Berezin EN, Ching TH, Canuto Jde S, Costa VO, Klering ÉM. Ineffectiveness for infants of immunization of mothers with pneumococcal capsular polysaccharide vaccine during pregnancy. Braz J Infect Dis 2009; 13 (02) 104-106
• 35 Hoang HT, Leuridan E, Maertens K. , et al. Pertussis vaccination during pregnancy in Vietnam: Results of a randomized controlled trial Pertussis vaccination during pregnancy. Vaccine 2016; 34 (01) 151-159
• 36 Villarreal Pérez JZ, Ramírez Aranda JM, de la O Cavazos M. , et al. Randomized clinical trial of the safety and immunogenicity of the Tdap vaccine in pregnant Mexican women. Hum Vaccin Immunother 2017; 13 (01) 128-135
• 37 Munoz FM, Bond NH, Maccato M. , et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA 2014; 311 (17) 1760-1769
• 38 National Institute for Allergy and Infectious Diseases. Novartis H1N1 vaccine in pregnant women. Study NCT00992719. Available at: http://clinicaltrials.gov/ct2/show/results/NCT00992719 . Accessed January 12, 2018
• 39 National Institute for Allergy and Infectious Diseases. 2010–2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women Available at: http://clinicaltrials.gov/ct2/show/NCT01173211?term=influenza%2C+infants&rank=168 . Accessed January 12, 2018
• 40 National Institute for Allergy and Infectious Diseases. A randomized, double-blind trial on the safety and immunogenicity of inactivated 2008/2009 trivalent influenza vaccine in pregnant women. Available at: http://clinicaltrials.gov/ct2/show/NCT01173211?term=influenza%2C+infants&rank=168 . Accessed January 12, 2018
• 41 Garcia LG. Clinical trial to evaluate the immunogenicity and safety of the 2011–2012 vaccine against seasonal influenza on pregnant women. Available at: http://clinicaltrials.gov/ct2/show/record/NCT01577316 . Accessed January 12, 2018
• 42 Groome M. Immunogenicity and Safety of Different Dosing Schedules of Trivalent Influenza Vaccine in HIV-infected Pregnant Women. Available at: https://clinicaltrials.gov/ct2/show/NCT01527825 . Accessed January 12, 2018
• 43 GlaxoSmithKline, Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women. Available at: https://clinicaltrials.gov/ct2/show/NCT02046148 . Accessed January 22, 2018
• 44 Medical Research Council Unit. The Gambia. Protecting from Pneumococcus in Early Life (The PROPEL Trial) (PROPEL). Available at: https://clinicaltrials.gov/ct2/show/NCT02628886 . Accessed January 22, 2018
• 45 Westat. Safety and Immunogenicity of Anti-Pneumococcal Vaccines in HIV-infected Pregnant Women. Available at: https://clinicaltrials.gov/ct2/show/NCT02717494 . Accessed January 22, 2018
• 46 Novavax. A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization. Available at: https://clinicaltrials.gov/ct2/show/NCT02624947 . Accessed January 22, 2018
• 47 Novavax. RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women. Available at: https://clinicaltrials.gov/ct2/show/NCT02247726 . Accessed January 22, 2018
• 48 Halperin S. Pertussis Maternal Immunization Study. Available at: https://www.clinicaltrials.gov/ct2/show/NCT00553228 . Accessed January 22, 2018
• 49 Omer S. Maternal Tdap Immunization in Guatemala. Available at: https://clinicaltrials.gov/ct2/show/NCT02301702 . Accessed January 22, 2018
• 50 National Institute of Allergy and Infectious Diseases (NIAID). A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT). Available at: https://clinicaltrials.gov/ct2/show/study/NCT00000751?show_locs=Y#locn . Accessed January 22, 2018